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Abstract: Rotavirus is a leading cause of severe acute gastroenteritis in children worldwide, and globally licensed
vaccines are available. To expedite the introduction of rotavirus vaccines in the national immunisation programme,
a simple, ecological method to monitor changes in the burden of rotavirus disease may be of great help. Here, we
report an application of a time-series analysis on a publicly-available dataset in Japan on the weekly number of
laboratory-confirmed rotavirus-positive samples over the last 5 year period between the 36th week of 2009 and the
35th week of 2014 during which rotavirus vaccines became marketed in Japan and presumed to reach an uptake
rate of at least 39% as a national average. Compared with the expected number of rotavirus detection based on the
preceding four rotavirus seasons, the number of rotavirus detection during the 2013–2014 season was 42.9% (95%
CI: 38.6, 47.8). This suggests that the use of rotavirus vaccine had a positive impact on reducing the burden of
rotavirus diarrhoea in Japan. This method, because of its simplicity and little cost, should be applicable to early
detection of the impact of rotavirus vaccine even in resource-poor countries where the World Health Organization
funded and implemented the sentinel surveillance programmes of laboratory-confirmed rotavirus cases.
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INTRODUCTION
Rotavirus is a major etiological agent of severe acute
gastroenteritis in infants and young children worldwide,
and causes each year an estimated 430,000 deaths that oc-
cur primarily among children in developing countries[1,
2]. While death toll is much smaller in high-income coun-
tries, rotavirus imposes a large health and economic bur-
den on their health-care systems [3–5]. In countries where
rotavirus vaccines were introduced in the national immuni-
sation schedules there have been ecological studies show-
ing the reduction in the detection rates of rotaviruses
among diarrheal samples [6–8]. Such studies highlight the
impact of rotavirus vaccines on infection rates, and may
encourage decision makers to include a rotavirus vaccine
into the national immunisation programme.
Like other high-income countries rotavirus gastroen-
teritis imposes a huge disease burden on the healthcare
system in Japan [2], where an attenuated human rotavirus
vaccine (Rotarix®: GlaxoSmithKline Biologicals, Rixen-
sart, Belgium) and a pentavalent reassortant rotavirus vac-
cine (RotaTeq®: Merck & Co., Inc., Whitehouse Station,
New Jerzy, USA) have been marketed since November
2011 and July 2012, respectively. An interim report by the
rotavirus vaccine working group under the Ministry of
Health, Labour and Welfare, Japan (www.mhlw.go.jp/file/
05-Shingikai-10601000.../0000029637.pdf) estimated that
the rotavirus vaccines were taken up by an average of 39%
of the age-eligible children in Japan between July 2012
and April 2013. According to the experiences in early
adopter countries of rotavirus vaccines, the impact of rota-
virus vaccines was detected soon after the vaccine intro-
duction in terms of reductions in the number or proportion
of laboratory-confirmed rotavirus infections available in
relatively simple surveillance database [6–8]. Thus, in an
attempt at detecting an early, preliminary indication of the
impact of rotavirus vaccine, we analysed the changes in
the number of rotaviruses detected by the prefectural pub-
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lic health laboratories across the country over the last four
years. As a control, we also analysed the changes in the
number of noroviruses, which should not be affected by
the use of rotavirus vaccine, over the last three years.
METHODS
Data source
In accordance with the law concerning the prevention
of infections and medical care for patients with infectious
diseases, there is in Japan an infectious agent surveillance
system in which clinical specimens collected at sentinel
hospitals were examined for relevant pathogens depending
on the nature of the case patients at the prefectural public
health laboratories and the information is then sent to the
National Institute of Infectious Diseases where the data
were collated and published on-line as Infectious Agents
Surveillance Report (http://idsc.nih.go.jp/iasr/index-j.htm).
From this online database, we extracted the weekly num-
bers of rotavirus and norovirus detected in prefectural pub-
lic health laboratories between September 2009 (week 36)
and August 2014 (week 35), and between September 2010
(week 36) and August 2014 (week 35), respectively.
Statistical analysis
We defined that the rotavirus vaccine was introduced
in September (in the 35th week) 2013, because the uptake
rates were expected to be very low in the first two rota-
virus seasons since Rotarix and RotaTeq were marketed in
November 2011 and July 2012, respectively (Fig. 1). Ex-
pected normal numbers of rotavirus positive samples for
each week after the rotavirus vaccine was introduced in
2013 were obtained as the season-specific average over the
four preceding years (from week 36 in 2009 to week 35 in
2013). This season-specific average was obtained by fit-
ting a Poisson generalized linear model with trigonometric
terms (sine and cosine functions) of annual cycle and har-
monics up to an order of six to the baseline four years [9].
The ratios of the observed against the expected number of
positive samples were calculated. Confidence intervals
(CIs) for the ratios were estimated from standard Poisson
assumptions augmented by a refinement to take account of
variability in the expected number of positive samples
from four years data (2009–2013) as well as variability in
the positive samples observed in the year after the vaccine
introduction (week 36 in 2013–week 35 in 2014). Specifi-
cally, 95% CIs for the ratios were calculated using the fol-
lowing formula [9]:
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Fig. 1. Time series for the number of rotavirus and norovirus positive samples each week between September (week 36) 2009 and
August (week 35) 2014 in Japan. The vertical, dotted line indicates week 36 in 2013. The data for norovirus between
September (week 36) 2009 and August (week 35) 2010 was missing.
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where, O: Observed number of positive samples, and E:
Expected number of positive samples.
As a comparison, the same procedures were per-
formed for the number of norovirus positive samples to es-
timate the observed/expected ratios and the 95% CIs.
Expected numbers of norovirus positive samples for each
week between week 36 in 2013 and week 35 in 2014 were
obtained as the season-specific average over the three pre-
ceding years (week 36 in 2010 to week 35 in 2013).
All analyses were conducted using the statistical
package Stata 12.0 (Stata Corporation, College Station,
Texas, USA).
RESULTS AND DISCUSSION
Compared with the expected number of rotavirus de-
tection based on the preceding four years between the 36th
week of 2009 and the 35th week of 2013, the number of
rotavirus detection during the one-year between the 36th
week of 2013 and the 35th week of 2014 was 42.9% (95%
CI: 38.6, 47.8) (Table 1 and Fig. 2a). By contrast, there
was virtually no change or only a slight decrease at best
(92.7%; 95% CI: 89.0, 96.7) observed for the number of
norovirus detection in the 2013/2014 season compared
with the preceding three seasons (Fig. 2b). Thus, there was
a reduction by 57% of the number of laboratory-confirmed
rotavirus cases but little of norovirus from the expected
number of cases.
Although observational studies can never prove cau-
sality, the closeness of the timing of the decreased case de-
tection to the timing of the vaccine introduction, the failure
to explain the decrease in the number of cases by normal
seasonality and no simultaneous marked reduction in the
number of norovirus cases make causality the most likely
explanation.
There are however a few limitations to this study.
First, we adjusted only for seasonality when estimating the
expected number of rotavirus-positive specimens. In other
words, we assumed that the epidemiology of rotavirus
would have remained the same if rotavirus vaccines had
Table 1. Observed and expected number of rotavirus and
norovirus positive samples between September








Rotavirus  367  854.5 0.429 0.386, 0.478
Norovirus 3006 3239.7 0.927 0.890, 0.967
* confidence interval
not been marketed. We also assumed the effect of the rota-
virus vaccines was negligible in the first two rotavirus sea-
sons during which Rotarix and RotaTeq were successively
marketed and the uptake rates were expected to be very
low. A modelling study simulating the rotavirus epidemiol-
ogy in Japan suggests that even stochastic variation in the
annual number of rotavirus cases can be as large as 29%
from the average [10], but the 57% reduction we observed
in the 2013/2014 season was far beyond the range of sto-
chastic variation. Virtual lack of the reduction in the num-
ber of norovirus-positive specimens further assures that the
2013/2014 season was not unusually mild to explain the as
large as 57% reduction in rotavirus-positive specimens.
Second, this analysis assumed that the vaccine was in-
troduced and administered to all eligible children in
September (in the 35th week) 2013, but the uptake rate of
either vaccine was likely to remain approximately 50%.
This would have biased the associations towards the null.
Third, as we entirely depended on the publicly availa-
ble database, we were not able to disaggregate the dataset.
Thus, for example, the change in age distribution of
rotavirus-positive cases from which clinical specimens
were derived was not evaluated. The changes in diagnostic
practices or reporting practices, if any, were not known.
Despite all these limitations, this time-series analysis
is simple to perform and quantitative to estimate the mag-
nitude of the impact of rotavirus vaccination. The introduc-
tion of rotavirus vaccine in the national immunisation
programme of Asian countries is far behind that of African
countries, despite both continents having a high burden of
rotavirus diarrhoea. For example, the Western Pacific
Region Office of the World Health Organization funded
and implemented the sentinel surveillance programme of
laboratory-confirmed rotavirus cases in each country with-
in the region since around 2012 in anticipating the intro-
duction of rotavirus vaccines. Although the programme
does not allow for calculation of the incidence rate of rota-
virus diarrhoea, the data obtained through this surveillance
should allow for a time-series analysis similar to that de-
scribed in this paper with almost no extra cost. What is
more important in this time-series analysis is to secure the
dataset that allows sufficiently accurate calculation of the
expected number of rotavirus-positive cases which can on-
ly be obtained before the vaccine introduction or during
the period of limited use of the vaccine in the market.
In conclusion, this time-series analysis of a publicly
available dataset on the weekly number of laboratory-
confirmed rotavirus-positive cases over the last 5 year pe-
riod, during which rotavirus vaccines became marketed
and presumed to reach an uptake rate of at least 39% as a
national average, strongly suggests that the use of rotavirus
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vaccine had a positive impact on reducing the burden of
rotavirus diarrhoea in Japan. Because of its simplicity and
little cost, it will be of considerable interest to examine this
method for early detection of the impact of rotavirus vac-
cine in resource-poor countries where the World Health
Organization funded and implemented the sentinel surveil-
lance programme of laboratory-confirmed rotavirus cases.
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Fig. 2. Observed and expected number of a) rotavirus and b) norovirus positive samples in each week between September (week
36) 2013 and August (week 35) 2014 in Japan. The shaded area shows 95% confidence intervals of the expected numbers.
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